Navigation Links
Some cancer drugs may block cellular 'cross talk' but not kill cancer cells
Date:12/22/2010

AURORA, Colo. (Dec. 22, 2010)A class of drugs thought to kill cancer cells may in fact block "cross talk" between the cancer cell and normal immune cells, resulting in reduced cancer growth and spreada discovery that could significantly alter the way cancer drugs are evaluated in the future.

Researchers at the University of Colorado Cancer Center demonstrated the discovery in bladder cancer, the fifth most common cancer in the United States. Bladder cancer will kill about 14,000 Americans this year, most of whom will die as a result of the disease's spread to other organs in a process called metastasis.

The scientists showed that endothelin-A receptor antagonist drugs are only effective at blocking the start of cancer spread to other organs, not treating large, established primary-or distant-site tumors. The study was published online Dec. 22, 2010, in the Journal of Clinical Investigation.

"We discovered that these drugs block the 'tumor host interactions' found at sites of metastasis, which is what reduces tumor growth at these sites," said lead author Dan Theodorescu, MD, PhD, director of the University of Colorado Cancer Center and professor of surgery and pharmacology at the University of Colorado School of Medicine. "However, unless the drugs are used early, they have minimal or no effect."

Endothelin-A receptor antagonist drugs block the action of a protein called endothelin 1 [ET-1], thought to be involved in stimulating cancer cell growth and spread. Theodorescu's lab discovered that ET-1 attracts immune cells called macrophages to cancer cells lodged in the lungs. The macrophages start making factors that stimulate the cancer cells in the lungs to growcalled metastatic colonizationwhich significantly decreases the patient's chance of survival.

In the past decade, two endothelin-A receptor antagonist drugsAbbott's atrasentan and AstraZeneca's zibotentanhave had difficulties in large phase 3 clinical trials. Both drugs were tested in a large number of patients with advanced cancer, and neither drug attained its desired effects. Most likely, Theodorescu said, the drugs were given after the window of opportunity for them to work had closed.

"Had we known this before the trials, we wouldn't have used them to try to reduce large, established tumors," he said. "We would have used them to try to suppress the appearance of metastasis. This new information has important implications for how we test drugs for effectiveness before human use and then on how we select patients in clinical trials with these agents, especially since many types of cancer secrete ET-1."


'/>"/>

Contact: Caitlin Jenney
caitlin.jenney@ucdenver.edu
303-315-6376
University of Colorado Denver
Source:Eurekalert

Related biology news :

1. Researchers discover genetic predisposition for breast, kidney cancers
2. Damon Runyon Cancer Research Foundation awards breakthrough scientists
3. Key information about breast cancer risk and development is found in junk DNA
4. Scientists discover powerful biomarker panel for the early detection of breast cancer
5. Blocking the critical structure that lets cancer cells move -- their feet
6. Missing molecules hold promise of therapy for pancreatic cancer
7. Scientists identify how virus triggers cervical and mouth cancer
8. A protein called cFLIP makes tumor cells in breast cancer resistant to treatments
9. Study: Osteoporosis drug reduces bone loss, tumor size in oral cancer
10. Ovarian cancer screening saves few lives
11. UCR scientists identify pomegranate juice components that could stop cancer from spreading
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2017)... and ITHACA, N.Y. , June 23, ... University, a leader in dairy research, today announced a ... to help reduce the chances that the global milk ... of this dairy project, Cornell University has become the ... the Food Supply Chain, a food safety initiative that ...
(Date:5/6/2017)... -- RAM Group , Singaporean based technology ... biometric authentication based on a novel  quantum-state ... perform biometric authentication. These new sensors are based on a ... Group and its partners. This sensor will have widespread ... security. Ram Group is a next generation sensor ...
(Date:4/13/2017)... , April 13, 2017 UBM,s Advanced Design ... will feature emerging and evolving technology through its ... Summits will run alongside the expo portion of the ... panels and demonstrations focused on trending topics within 3D ... design and manufacturing event will take place June 13-15, 2017 ...
Breaking Biology News(10 mins):
(Date:10/12/2017)... ... October 12, 2017 , ... The ... three Winners and six Finalists of the 2017 Blavatnik Regional Awards for Young ... Family Foundation and administered by the New York Academy of Sciences to honor ...
(Date:10/12/2017)... ... October 12, 2017 , ... BioMedGPS announces expanded ... of its newest module, US Hemostats & Sealants. , SmartTRAK’s US Market for ... fibrin sealants, synthetic sealants and biologic sealants used in surgical applications. BioMedGPS estimates ...
(Date:10/11/2017)... Charlotte, N.C. (PRWEB) , ... October 11, 2017 ... ... ARCS® Foundation President Andi Purple announced Dr. Suneel I. Sheikh, the ... Laboratories ( ASTER Labs ), Inc. has been selected for membership in ...
(Date:10/11/2017)... ... October 11, 2017 , ... ComplianceOnline’s Medical Device Summit is back ... 8th June 2018 in San Francisco, CA. The Summit brings together current and former ... CEOs, board directors and government officials from around the world to address key issues ...
Breaking Biology Technology: